What is he best known for?
The fields of study he is best known for:
Stefan Niemann spends much of his time researching Mycobacterium tuberculosis, Genetics, Tuberculosis, Mycobacterium tuberculosis complex and DNA profiling.
His studies deal with areas such as Drug resistance, Microbiology, Whole genome sequencing and Genotype as well as Mycobacterium tuberculosis.
His Drug resistance research is multidisciplinary, incorporating perspectives in Pyrazinamide and Rifampicin.
His Tuberculosis research includes elements of Evolutionary biology, Population genetics, Immunology and Virology.
In his study, which falls under the umbrella issue of Mycobacterium tuberculosis complex, Antibacterial agent is strongly linked to Isoniazid.
His work in DNA profiling covers topics such as Genetic marker which are related to areas like Genotyping Techniques.
His most cited work include:
- Proposal for Standardization of Optimized Mycobacterial Interspersed Repetitive Unit-Variable-Number Tandem Repeat Typing of Mycobacterium tuberculosis (1055 citations)
- Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology (899 citations)
- Variable host-pathogen compatibility in Mycobacterium tuberculosis. (781 citations)
What are the main themes of his work throughout his whole career to date?
Stefan Niemann mainly focuses on Mycobacterium tuberculosis, Tuberculosis, Mycobacterium tuberculosis complex, Genetics and Drug resistance.
The Mycobacterium tuberculosis study combines topics in areas such as Virology, Whole genome sequencing, Typing, Microbiology and Genotype.
The various areas that Stefan Niemann examines in his Tuberculosis study include Multiple drug resistance, Molecular epidemiology, Immunology and Internal medicine.
His Mycobacterium tuberculosis complex study combines topics in areas such as Genetic diversity, Genotyping, Mycobacterium and Single-nucleotide polymorphism.
His Genetics study frequently draws connections to other fields, such as Mycobacterium bovis.
His study looks at the relationship between Drug resistance and fields such as rpoB, as well as how they intersect with chemical problems.
He most often published in these fields:
- Mycobacterium tuberculosis (57.54%)
- Tuberculosis (52.00%)
- Mycobacterium tuberculosis complex (32.62%)
What were the highlights of his more recent work (between 2018-2021)?
- Tuberculosis (52.00%)
- Mycobacterium tuberculosis (57.54%)
- Mycobacterium tuberculosis complex (32.62%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Tuberculosis, Mycobacterium tuberculosis, Mycobacterium tuberculosis complex, Drug resistance and Genetics.
The concepts of his Tuberculosis study are interwoven with issues in Multiple drug resistance and Internal medicine.
His biological study spans a wide range of topics, including Evolutionary biology, Whole genome sequencing, Antibiotic resistance, Isoniazid and Computational biology.
Stefan Niemann works mostly in the field of Mycobacterium tuberculosis complex, limiting it down to concerns involving Genotype and, occasionally, Microbiology and Antibiotics.
His Drug resistance research is multidisciplinary, relying on both Pyrazinamide, Ethionamide, Ethambutol and Virology.
As a part of the same scientific family, Stefan Niemann mostly works in the field of Genetics, focusing on INHA and, on occasion, Isoniazid resistance.
Between 2018 and 2021, his most popular works were:
- Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. (69 citations)
- The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. (32 citations)
- Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment. (27 citations)
In his most recent research, the most cited papers focused on:
Stefan Niemann spends much of his time researching Tuberculosis, Mycobacterium tuberculosis, Mycobacterium tuberculosis complex, Drug resistance and Genetics.
His Tuberculosis research is multidisciplinary, incorporating elements of Disease, Pediatrics and Cohort.
His study in the fields of Mycobacterium africanum under the domain of Mycobacterium tuberculosis overlaps with other disciplines such as Extramural.
His work in Drug resistance addresses subjects such as Ethambutol, which are connected to disciplines such as Nanopore sequencing and Pyrazinamide.
His studies in Genetics integrate themes in fields like Mycobacteria growth indicator tube and Isoniazid.
His Genotyping research incorporates themes from Mycobacterium bovis, Variable number tandem repeat, Typing and Mycobacterium.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
